PharmaSEAL International Limited

PharmaSEAL International Limited
Contents Page
For the year ended 31 March 2026

Accountants' Report	1
Statement of Financial Position	2
Notes to the Financial Statements	3

PharmaSEAL International Limited Accountants' Report For the year ended 31 March 2026
Chartered Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of PharmaSEAL International Limited for the year ended 31 March 2026. In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of PharmaSEAL International Limited for the year ended 31 March 2026 which comprise of the Profit and Loss Account, the Balance Sheet and the related notes from the companys accounting records and from information and explanations you have given us. As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/members/regulations-standards-and-guidance. This report is made solely to the Board of Directors of PharmaSEAL International Limited , as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of PharmaSEAL International Limited and state those matters that we have agreed to state to the Board of Directors of PharmaSEAL International Limited , as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than PharmaSEAL International Limited and its Board of Directors as a body for our work or for this report. It is your duty to ensure that PharmaSEAL International Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of PharmaSEAL International Limited . You consider that PharmaSEAL International Limited is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the accounts of PharmaSEAL International Limited . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts. .................................................... M Ahmed & Co Accountants Ltd Chartered Accountants 83 Park Road Nottingham Nottinghamshire NG9 4DE 30 July 2026 1

PharmaSEAL International Limited
Accountants' Report
For the year ended 31 March 2026

Chartered Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of PharmaSEAL International Limited for the year ended 31 March 2026.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of PharmaSEAL International Limited for the year ended 31 March 2026 which comprise of the Profit and Loss Account, the Balance Sheet and the related notes from the companys accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/members/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of PharmaSEAL International Limited , as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of PharmaSEAL International Limited and state those matters that we have agreed to state to the Board of Directors of PharmaSEAL International Limited , as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than PharmaSEAL International Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that PharmaSEAL International Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of PharmaSEAL International Limited . You consider that PharmaSEAL International Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of PharmaSEAL International Limited . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

....................................................
M Ahmed & Co Accountants Ltd
Chartered Accountants
83 Park Road
Nottingham
Nottinghamshire
NG9 4DE
30 July 2026

1

PharmaSEAL International Limited
Statement of Financial Position
As at 31 March 2026

	Notes	2026 £	2025 £
Fixed assets
Tangible fixed assets	3	2,085	2,203
		2,085	2,203
Current assets
Debtors		117,169	128,152
Cash at bank and in hand		289,577	512,953
		406,746	641,105
Creditors: amount falling due within one year		(469,512)	(533,614)
Net current assets		(62,766)	107,491

Total assets less current liabilities		(60,681)	109,694
Creditors: amount falling due after more than one year		(20,556)	(22,294)
Net assets		(81,237)	87,400

Capital and reserves
Called up share capital		6	6
Share Premium Account		2,693,908	2,693,908
Profit and loss account		(2,775,151)	(2,606,514)
Shareholders' funds		(81,237)	87,400

For the year ended 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006 the profit and loss account has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).

The financial statements were approved by the board of directors on 30 July 2026 and were signed on its behalf by:

-------------------------------
Daljit Singh CHEEMA
Director

2

PharmaSEAL International Limited
Notes to the Abridged Financial Statements
For the year ended 31 March 2026

General Information

PharmaSEAL International Limited is a private company, limited by shares, registered in England and Wales, registration number 09993255, registration address Ingenuity Centre Nottingham University Innovation Park, Triumph Road, Nottingham, NG7 2TU.

The presentation currency is £ sterling.

1.

Accounting policies

Significant accounting policies

Statement of compliance

These financial statements have been prepared in compliance with FRS 102(1A) The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared under the historical cost convention.

Going concern basis

In preparing these financial statements, the directors have assessed whether there are any material uncertainties related to events or conditions that cast significant doubt upon the company's ability to continue as a going concern. In making this assessment, the directors take into account all available information about the future which is at least 12 months from the date that the financial statements are authorised for issue.

The directors consider that the company has adequate resources to continue in business for the foreseeable future and that it is appropriate to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, Value Added Tax and other sales taxes.

Research and development expenditure

Research and development expenditure is charged to the profit and loss account in the period in which it is incurred.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rate of exchange ruling at the statement of financial position date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All foreign exchange differences are included to the profit and loss account.

Taxation

Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Fixtures and Fittings	33% Reducing Balance
Computer Equipment	33% Reducing Balance

2.	Average number of employees Average number of employees during the year was 8 (2025 : 8).

3.

Tangible fixed assets

Cost or valuation	Fixtures and Fittings	Computer Equipment	Total
	£	£	£
At 01 April 2025	392	14,801	15,193
Additions	-	924	924
Disposals	-	-	-
At 31 March 2026	392	15,725	16,117
Depreciation
At 01 April 2025	392	12,598	12,990
Charge for year	-	1,042	1,042
On disposals	-	-	-
At 31 March 2026	392	13,640	14,032
Net book values
Closing balance as at 31 March 2026	-	2,085	2,085
Opening balance as at 01 April 2025	-	2,203	2,203

3

Registered Number: 09993255
England and Wales
PHARMASEAL INTERNATIONAL LIMITED

Abridged Accounts

Period of accounts Start date: 01 April 2025 End date: 31 March 2026